Cornerstone Planning Group
ABCL icon

Cornerstone Planning Group’s AbCellera Biologics ABCL Stock Holding History

Cornerstone Planning Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2,000
Closed -$11.5K – 182
2026
Q2 		$11.5K Hold
2,000
– – ﹤0.01% 852
2026
Q1 		$9.32K Buy
2,000
+250
+14% +$900 ﹤0.01% 915
2025
Q4 		$6.82K Buy
1,750
+1,716
+5,047% +$7.66K ﹤0.01% 892
2025
Q3 		$741 Buy
+34
New +$150 ﹤0.01% 1385

Other funds holding ABCL

TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Guardian Partners
Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
DKM Wealth Management
DKM Wealth Management Stockton, California $158M AUM 11.62% 1-Year Est. Return
Lantern Wealth Advisors
Lantern Wealth Advisors Melville, New York $232M AUM 16.88% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Pacifica Partners
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
Princeton Global Asset Management
Princeton Global Asset Management Princeton, New Jersey $692M AUM 20.31% 1-Year Est. Return

Cornerstone Planning Group's ABCL Position: Q3 2026 in Review

Cornerstone Planning Group sold out of AbCellera Biologics (ABCL) in Q3 2026, closing a stake of 2,000 shares — an estimated $11.5K sold.

Cornerstone Planning Group first reported a position in ABCL in Q3 2025 and held it in 4 quarters. The position peaked at $11.5K in Q2 2026. 12 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Cornerstone Planning Group reported no remaining AbCellera Biologics position as of Q3 2026 after selling out during the quarter.
  • Cornerstone Planning Group sold 2,000 AbCellera Biologics shares in Q3 2026, an estimated $11.5K.
  • Cornerstone Planning Group first reported a position in AbCellera Biologics in Q3 2025 and held it in 4 quarters.
  • Cornerstone Planning Group's AbCellera Biologics position peaked at $11.5K in Q2 2026.
  • 12 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.